What is Cullgen?
Founded in 2018 and based in San Diego, California, Cullgen is pioneering a proprietary technology platform centered on ubiquitin-mediated, small molecule-induced target elimination. This cutting-edge approach aims to address diseases with significant unmet therapeutic needs by leveraging recent advancements in protein degradation science. The company's focus on first-in-class new chemical entities positions it at the forefront of biopharmaceutical innovation, seeking to create transformative treatments.
How much funding has Cullgen raised?
Cullgen has raised a total of $106M across 3 funding rounds:
Series A
$16M
Series B
$50M
Series C
$40M
Series A (2019): $16M, investors not publicly disclosed
Series B (2021): $50M led by South China Venture Capital, MSA Capital, Octagon Capital, Height Capital Management, and 3E Bioventures Capital
Series C (2023): $40M supported by GNI Group, AstraZeneca, and Wuxi Venture Capital Group
Key Investors in Cullgen
GNI Group
GNI Group is a global healthcare company based in Japan, dedicated to drug discovery, manufacturing, and sales, with a mission to provide hope to patients worldwide by developing innovative solutions for unmet medical needs.
AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Wuxi Venture Capital Group
Wuxi Venture Capital Group is a leading high-tech venture capital firm in Wuxi, China, focusing on strategic investments in key industries such as integrated circuits, IoT, and advanced manufacturing, supporting technological innovation and growth.
What's next for Cullgen?
The recent major strategic investment signals a pivotal growth phase for Cullgen, likely enabling the company to accelerate its research and development pipeline, expand its clinical trial activities, and further scale its operations. This substantial backing from strategic partners suggests a strong validation of Cullgen's technology and therapeutic targets, paving the way for potential future breakthroughs in disease treatment and market expansion.
See full Cullgen company page
